Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients
SA Fayek, W Mantipisitkul, F Rasetto… - HPB, 2010 - Wiley Online Library
Objectives: Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients
SA Fayek, W Mantipisitkul, F Rasetto… - HPB, 2010 - pure.johnshopkins.edu
Objectives: Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients
SA Fayek, W Mantipisitkul, F Rasetto… - HPB: the official …, 2010 - pubmed.ncbi.nlm.nih.gov
Objectives Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
[HTML][HTML] Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients
SA Fayek, W Mantipisitkul, F Rasetto… - HPB, 2010 - hpbonline.org
Objectives Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
[HTML][HTML] Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients
SA Fayek, W Mantipisitkul, F Rasetto… - HPB, 2010 - hpbonline.org
Objectives Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.
SA Fayek, W Mantipisitkul, F Rasetto… - HPB: the Official …, 2010 - europepmc.org
Objectives Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
[HTML][HTML] Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients
SA Fayek, W Mantipisitkul, F Rasetto… - HPB, 2010 - Elsevier
Objectives Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
[HTML][HTML] Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients
SA Fayek, W Mantipisitkul, F Rasetto… - HPB: The Official …, 2010 - ncbi.nlm.nih.gov
Objectives: Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.
SA Fayek, W Mantipisitkul, F Rasetto… - HPB: the Official …, 2010 - europepmc.org
Objectives Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …